Ema committee for medicinal products for human use (chmp) adopts positive opinion recommending authorization for the use of the moderna covid-19 vaccine in children (6-11 years) in the european union

Announcement follows chmp's previous decision to adopt a positive opinion recommending marketing authorization for moderna's covid-19 vaccine to include adolescents 12 years of age and older. cambridge, ma / accesswire / february 24, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has adopted a positive opinion recommending a variation to the conditional marketing authorization (cma) to include a 50 Μg two-dose series of spikevax, the company's vaccine against covid-19, in children ages 6-11 years.
MRNA Ratings Summary
MRNA Quant Ranking